Independent Investigator Initiates Phase 1 Study of Biodel’s Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps.
Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is used as a means to provide intensive insulin therapy to patients with diabetes. Currently available prandial insulins are used in pumps, but often are not absorbed rapidly enough to achieve optimal mealtime glucose control. It is believed that an ultra-rapid-acting insulin will be better suited for pump therapy than currently marketed mealtime insulin analogs.
You can view Biodel’s press release here - http://investor.biodel.com/releasedetail.cfm?ReleaseID=575640
About Biodel:
www.biodel.com











No comments yet.